Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young-Joo Jin, Seung-seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, YoungRok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, Dae Won Jun, Seung Up Kim, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol 2024;30(Suppl):S5-S105. Published online August 19, 2024
Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis” Haiyu Wang, Jinjun Chen Clinical and Molecular Hepatology.2026; 32(1): e58. CrossRef
Refining portal hypertension assessment: The clinical significance of spleen stiffness measurement in the Baveno VII Era: Editorial on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis” Do Seon Song Clinical and Molecular Hepatology.2026; 32(1): 400. CrossRef
Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement Joseph Rabbat, Boyu Yang, Hye Won Lee, Huapeng Lin, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jérôme Boursier, José Luis Calleja, George Boon-Bee Goh, Wah-Kheong Chan, Rocio Gallego-Durán, Clinical and Molecular Hepatology.2026; 32(1): 289. CrossRef
Non-invasive Risk-based Surveillance Strategy for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Ji Won Han The Korean Journal of Gastroenterology.2026; 86(1): 62. CrossRef
2025 KASL clinical practice guidelines for management of hepatitis C Eun Sun Jang, Nae Yun Heo, Jae Yoon Jeong, Jung Gil Park, Do Seon Song, Eun Ju Cho, Chang Hun Lee, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jung Clinical and Molecular Hepatology.2026; 32(1): 1. CrossRef
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis” Hee Yeon Kim, Miyoung Choi, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(1): e48. CrossRef
Non-Invasive Liver Fibrosis Test Using Shear Wave Elastography Ji Won Han The Korean Journal of Medicine.2025; 100(1): 26. CrossRef
Influence of Sex in the Development of Liver Diseases Jie-Wen Zhang, Nan Zhang, Yi Lyu, Xu-Feng Zhang Seminars in Liver Disease.2025; 45(01): 015. CrossRef
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang Clinical and Molecular Hepatology.2025; 31(Suppl): S1. CrossRef
Noninvasive identification of metabolic dysfunction–associated steatohepatitis (INFORM MASH): a retrospective cohort and disease modeling study G. Craig Wood, Anthony Hoovler, Rakesh Luthra, Christopher D. Still, Hamzah Shariff, Matthew Still, Jonathan Hayes, Peter Benotti, Chioma Uzoigwe Expert Review of Gastroenterology & Hepatology.2025; 19(4): 427. CrossRef
Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liv Ji Won Han, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(2): e152. CrossRef
The association between modified cardiometabolic index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study Yanjun Guo, Wei Su, Lulong Tao, Guoxin Zhang, Kun Wang BMC Gastroenterology.2025;[Epub] CrossRef
Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C Beom Kyung Kim Journal of Gastroenterology and Hepatology.2025; 40(8): 1855. CrossRef
Novel Insights into Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C Patients Guanlan Liu, Li Liu, Xing Yang, Qihao Wang, Mingqin Qian Journal of Clinical and Experimental Hepatology.2025; 15(6): 102610. CrossRef
A Case Report of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) with Improved Cardiometabolic Risk Factors Following Treatment with Saenggangunbi-tang Eun Kyung Lee, Min Jeong Park, Youngchul Kim, Jang-Hoon Lee The Journal of Internal Korean Medicine.2025; 46(2): 303. CrossRef
Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease Hye Won Lee, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Clinical and Molecular Hepatology.2025; 31(3): 1018. CrossRef
Performance of APRI and FIB-4 Scores Compared to FibroScan: A Cross-Sectional Study in a Black Sub-Saharan African Population Jean-Bonny Nsumbu, Jean-Robert Makulo, Trésor Mutombo Tshiswaka, Christian Kisoka Lusunsi, Charles Nlombi Mbendi Hepatic Medicine: Evidence and Research.2025; Volume 17: 27. CrossRef
Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis Toshikazu Kohira, Satoshi Oeda, Erina Eto, Yoshihito Kubotsu, Misa Norita, Kaori Inoue, Nagisa Hara, Shotaro Noge, Kenichi Tanaka, Shigenobu Yoshimura, Noriko Oza, Keizo Anzai, Yuichiro Eguchi, Cheng Han Ng, Daniel Q. Huang, Mark D. Muthiah, Atsushi Kawag Scientific Reports.2025;[Epub] CrossRef
Longitudinal Effects of Glecaprevir/Pibrentasvir on Liver Function, Fibrosis, and Hepatocellular Carcinoma Risk in Chronic Hepatitis C: A Prospective Multicenter Cohort Study Jung Hee Kim, Jae Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Yewan Park, Gi-Ae Kim, Seong Kyun Na, Young-Sun Lee, Jeong Han Kim Medicina.2025; 61(9): 1601. CrossRef
Comment on ‘Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank’ by T. S. Lim et al.—Authors' Reply Tae Seop Lim, Sujin Kwon, Sung A Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef
Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis Brian Lee, Ussama Ghumman, Lisa D. Pedicone, Andres Gomez Aldana, Eric Lawitz Clinical and Molecular Hepatology.2025; 31(4): 1167. CrossRef
Discovery of ultrasound-derived fat fraction as a non-invasive tool for MASLD diagnosis Huiru Jin, Mengfan Jiao, Chengxiao Yu, Tingting Ren, Qingling Chen, Zixing Dai, Erfu Xie, Longfeng Jiang, Yuwen Li European Journal of Medical Research.2025;[Epub] CrossRef
Mistakes in the utilization of vibration-controlled transient elastography in the evaluation of liver fibrosis: a narrative review Madunil Anuk Niriella, Uditha Bandara Dassanayake, Charith Priyanga Madurapperuma, Indeewari Prathibha Wijesingha, Arjuna Priyadarshin De Silva, Hithnadura Janaka de Silva Expert Review of Gastroenterology & Hepatology.2025; 19(12): 1299. CrossRef
Enhanced Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma Using Age-male-albumin-bilirubin-platelet (aMAP) and Liver Stiffness Assessed by Vibration-controlled Transient Elastography Hye Yeon Chon, Hyung Joon Yim, Seok-Jae Heo, Su Jong Yu, Ja Kyung Kim, Sang Hoon Ahn, Grace Lai-Hung Wong, Jimmy Che-To Lai, Terry Cheuk-Fung Yip, Sang Gyune Kim, Yeon Seok Seo, Seung Up Kim Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
A Novel Deep Learning Framework for Liver Fibrosis Staging and Etiology Diagnosis Using Integrated Liver–Spleen Elastography Kai Yang, Fei Chen, Aiping Tian, Long Deng, Xiaorong Mao Diagnostics.2025; 15(23): 2986. CrossRef
Shear-Wave Elastography: Principles, Techniques, and Clinical Considerations Jae Seung Lee Clinical Ultrasound.2025; 10(2): 53. CrossRef
Vibration-Controlled Transient Elastography in Chronic Liver Disease: Current Research Insights Ho Soo Chun Clinical Ultrasound.2025; 10(2): 69. CrossRef
Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease Jung Hwan Yu The Korean Journal of Medicine.2024; 99(5): 232. CrossRef
Noninvasive Imaging Test to Assess Liver Fibrosis: Vibration-controlled Transient Elastography Mi Na Kim The Korean Journal of Gastroenterology.2024; 84(5): 201. CrossRef
Non-Invasive Test for Assessment of Liver Fibrosis in Chronic Hepatitis B Ye Ji Jun, Minjong Lee, Ho Soo Chun, Tae Hun Kim The Korean Journal of Gastroenterology.2024; 84(5): 206. CrossRef
Serological Markers to Assess Liver Fibrosis and Their Roles Beom Kyung Kim The Korean Journal of Gastroenterology.2024; 84(5): 195. CrossRef
Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography Han Ah Lee Clinical Ultrasound.2024; 9(2): 70. CrossRef
Research trends on the quality of life in patients with metabolic dysfunction-associated fatty liver diseases: a scientific metrology study Can Huang, Meng Chen, Yanfang Sun, Lin Zhang, Wei Liu Frontiers in Nutrition.2025;[Epub] CrossRef
Beyond the liver: targeting the hepatic microenvironment and multi-organ networks for innovative MASH therapy Rong Fu, Fuyuan Zhang, Jingran Fu, Yuqian Li, Xuanzhe Zhu, Qian Ding, Yi-Zhun Zhu Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean? Eugene Han, Yong-ho Lee Clinical and Molecular Hepatology.2023; 29(4): 980. CrossRef
Ji Hyun Kim, Baek Gyu Jun, Minjong Lee, Hye Ah Lee, Tae Suk Kim, Jeong Won Heo, Da Hye Moon, Seong Hee Kang, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim, Dae Hee Choi
Clin Mol Hepatol 2022;28(3):540-552. Published online May 6, 2022
Background/Aims Sepsis-3 criteria and quick Sequential Organ Failure Assessment (qSOFA) have been advocated to be used in defining sepsis in the general population. We aimed to compare the Sepsis-3 criteria and Chronic Liver Failure-SOFA (CLIF-SOFA) scores as predictors of in-hospital mortality in cirrhotic patients admitted to the emergency department (ED) for infections.
Methods A total of 1,622 cirrhosis patients admitted at the ED for infections were assessed retrospectively. We analyzed their demographic, laboratory, and microbiological data upon diagnosis of the infection. The primary endpoint was inhospital mortality rate. The predictive performances of baseline CLIF-SOFA, Sepsis-3, and qSOFA scores for in-hospital mortality were evaluated.
Results The CLIF-SOFA score proved to be significantly better in predicting in-hospital mortality (area under the receiver operating characteristic curve [AUROC], 0.80; 95% confidence interval [CI], 0.78–0.82) than the Sepsis-3 (AUROC, 0.75; 95% CI, 0.72–0.77, P<0.001) and qSOFA (AUROC, 0.67; 95% CI, 0.64–0.70; P<0.001) score. The CLIF-SOFA, CLIF-C-AD scores, Sepsis-3 criteria, septic shock, and qSOFA positivity were significantly associated with in-hospital mortality (adjusted hazard ratio [aHR], 1.24; 95% CI, 1.19–1.28; aHR, 1.13; 95% CI, 1.09–1.17; aHR, 1.19; 95% CI, 1.15–1.24; aHR, 1.88; 95% CI, 1.42–2.48; aHR, 2.06; 95% CI, 1.55–2.72; respectively; all P<0.001). For CLIF-SOFA scores ≥6, in-hospital mortality was >10%; this is the cutoff point for the definition of sepsis.
Conclusions Among cirrhosis patients presenting with infections at the ED, CLIF-SOFA scores showed a better predictive performance for mortality than both Sepsis-3 criteria and qSOFA scores, and can be a useful tool of risk stratification in cirrhotic patients requiring timely intervention for infection.
Citations
Citations to this article as recorded by
Interpretable model for early prediction of 28-day mortality in patients with cirrhosis and sepsis: a multi-cohort ICU study Xin Xu, Jingjing Li, Haijing Yu, Jiaquan Huang BMC Gastroenterology.2026;[Epub] CrossRef
A Serum DLL1 and CRP dual-marker model for bacterial infection detection in patients with decompensated cirrhosis: A dual-cohort diagnostic study Juanjun Huang, Luhu Yu, Debin Zeng, Yulin Wang, Zhi Wang, Jian Chen, Wei Zhu Science Progress.2025;[Epub] CrossRef
Correlation between systemic inflammatory response syndrome and prognosis of patients with cirrhosis and hepatic encephalopathy Kaiyue Zhang, Ziqun Qu, Rongyu Tang, Hongliang Dong, Jing Fan, Wei Ye BMC Gastroenterology.2025;[Epub] CrossRef
Management of patients with cirrhosis in the emergency department: Implications for hospitalization outcomes Sandeep Sikerwar, Sohrab Zand, Peter Steel, Arun Jesudian Liver Transplantation.2024; 30(1): 94. CrossRef
Current Status of Prognostic Evaluation Model and Treatment of Acute-on-Chronic Liver Failure 念 刘 Advances in Clinical Medicine.2024; 14(04): 2500. CrossRef
Prevalence and predictors of multidrug-resistant bacteremia in liver cirrhosis Aryoung Kim, Byeong Geun Song, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Myung Ji Goh The Korean Journal of Internal Medicine.2024; 39(3): 448. CrossRef
Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Ya Clinical and Molecular Hepatology.2024; 30(3): 388. CrossRef
Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment” Do Seon Song, Dong Joon Kim Clinical and Molecular Hepatology.2024; 30(4): 1012. CrossRef
Cirrhosis Management in the Intensive Care Unit Thomas N. Smith, Alice Gallo de Moraes, Douglas A. Simonetto Seminars in Liver Disease.2023; 43(01): 117. CrossRef
Hepatitis B virus (HBV) affects approximately 250 million patients worldwide, resulting in the progression to cirrhosis and hepatocellular carcinoma, which are serious public health problems. Although universal vaccination programs exist, they are only prophylactic and not curative. In the HBV life cycle, HBV forms covalently closed circular DNA (cccDNA), which is the viral minichromosome, in the nuclei of human hepatocytes and makes it difficult to achieve a complete cure with the current nucleos(t)ide analogs and interferon therapies. Current antiviral therapies rarely eliminate cccDNA; therefore, lifelong antiviral treatment is necessary. Recent trials for antiviral treatment of chronic hepatitis B have been focused on establishing a functional cure, defined by either the loss of hepatitis B surface antigen, undetectable serum HBV DNA levels, and/or seroconversion to hepatitis B surface antibody. Novel therapeutic targets and molecules are in the pipeline for early clinical trials aiming to cure HBV infection. The ideal strategy for achieving a long-lasting functional or complete cure might be using combination therapies targeting different steps of the HBV life cycle and immunomodulators. This review summarizes the current knowledge about novel treatments and combination treatments for a complete HBV cure.
Citations
Citations to this article as recorded by
The Sustainable Goal of Eliminating Hepatitis B, Functional Cure, and the Prospect of NASVAC: A Review Mamun Al Mahtab, Julio CA Rubido, Gerardo E Guillén, Eduardo Penton, Osamu Yoshida, Yoichi Hiasa, Sakirul Khan, Md Abdur Rahim, Noor-E-Alam Mohammad, Ahmed L Moben, Rokshana Begum, Musarrat Mahtab, Sheikh MF Akbar Euroasian journal of hepato-gastroenterology.2026; 15(2): 178. CrossRef
Predictive factors for clinical cure in the treatment of HBeAg(−) chronic hepatitis B or compensated cirrhosis: a prospective observational study Yan-Qing Lv, Ru-Hua Guo, Kun-Yu Liu, Jia-Jie Li, Hui-Fan Ji Frontiers in Medicine.2025;[Epub] CrossRef
Cobalt Chloride–Mimicked Hepatocyte Cell Hypoxia Induces TREX1, Leading to Hepatitis B Virus Restriction Rodolphe Suspène, Vincent Caval, Pierre Khalfi, Emmanuelle Pitré, Agnès Marchio, Pascal Pineau, Jean-Pierre Vartanian The Journal of Infectious Diseases.2025; 231(6): 1559. CrossRef
The sV184A Variant in HBsAg Specific to HBV Subgenotype C2 Leads to Enhanced Viral Replication and Apoptotic Cell Death Induced by PERK‐eIF2α‐CHOP‐Mediated ER Stress Yu‐Min Choi, Dong Hyun Kim, Eun Ju Cho, Ziyun Kim, Junghwa Jang, Hyunsoo Kim, Su Jong Yu, Bum‐Joon Kim Journal of Medical Virology.2025;[Epub] CrossRef
Prediction of long-term HBsAg seroclearance in patients with HBeAg-negative chronic hepatitis B Hae Lim Lee, Soon Kyu Lee, Ji Won Han, Hyun Yang, Heechul Nam, Pil Soo Sung, Hee Yeon Kim, Sung Won Lee, Do Seon Song, Jung Hyun Kwon, Chang Wook Kim, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang JHEP Reports.2025; 7(7): 101391. CrossRef
Hepatocellular carcinoma in Korea: an analysis of the 2016-2018 Korean Nationwide Cancer Registry Jihyun An, Young Chang, Gwang Hyeon Choi, Won Sohn, Jeong Eun Song, Hyunjae Shin, Jae Hyun Yoon, Jun Sik Yoon, Hye Young Jang, Eun Ju Cho, Ji Won Han, Suk Kyun Hong, Ju-Yeon Cho, Kyu-Won Jung, Eun Hye Park, Eunyang Kim, Bo Hyun Kim Journal of Liver Cancer.2025; 25(1): 109. CrossRef
Functional Cure for Hepatitis B Virus: Challenges and Achievements Oren Shechter, Daniel G. Sausen, Harel Dahari, Andrew Vaillant, Scott J. Cotler, Ronen Borenstein International Journal of Molecular Sciences.2025; 26(8): 3633. CrossRef
Impact of hepatitis B surface antigen quantification on achieving a functional cure in patients with chronic hepatitis B: A systematic review and meta-analysis Shun Li, Lichen Shi, Cheng Huang, Min Li, Tongtong Meng, Hao Wang, Xinyu Zhao, Xiaoqian Xu, Hong You, Jidong Jia, Yuanyuan Kong Annals of Hepatology.2025; 30(2): 101921. CrossRef
A review of the progress and challenges of developing dendritic-based vaccines against hepatitis B virus (HBV) Ali Ameri, Hossein Gandomkar, Hanan Hassan Ahmed, Radhwan Abdul Kareem, Hayder Naji Sameer, Ahmed Yaseen, Zainab H. Athab, Mohaned Adil, Iman Ghasemzadeh Pathology - Research and Practice.2025; 271: 156025. CrossRef
mRNA-LNP vaccines against hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models María José Limeres, Rocio Gambaro, Malin Svensson, Silvia Fraude-El Ghazi, Leah Pretsch, Daniel Frank, German A. Islan, Ignacio Rivero Berti, Matthias Bros, Ying K. Tam, Hiromi Muramatsu, Norbert Pardi, Stephan Gehring, Maximiliano L. Cacicedo Molecular Therapy.2025; 33(9): 4156. CrossRef
Novel Therapeutics for Hepatocellular Carcinoma Mohamed I. Elsaid, Ashish Manne Clinics in Liver Disease.2025; 29(4): 673. CrossRef
Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D Junjie Liu, Tong Yuan, Lin Xue, Huifang Liang Virology Journal.2025;[Epub] CrossRef
Advances in the computational development of hepatitis B virus capsid assembly modulators Ke Liu, Shaoqing Du, Weiqiao Deng, Zongjin Qu, Xueping Hu Drug Discovery Today.2025; 30(10): 104458. CrossRef
Emerging Trends and Future Directions in the Development of Anti-hepatitis B Therapies: A Horizon Scanning Review Kaijie Yao, Hao Feng, Ying Chen, Yun Bao, Mengxia Yan, Wen Li, Bin Wu Clinical Drug Investigation.2025; 45(10): 681. CrossRef
Magnitude of Hepatitis B virus and associated factors among chronic liver disease patients admitted to the medical ward at Sheikh Hassen Yabare Comprehensive Specialized Hospital, Jigjiga, Ethiopia: a retrospective study Ramadan Budul Yusuf, Getnet Addisu, Ahmed Mohammed Ibrahim, Terefe Gebre, Seid Muhumed Abdilaahi, Bilan Ali Ahmed, Abdulahi Hussen Abdinur, Girma Tadesse Wedajo, Mohamed Omar Osman, Tebelay Dilnessa PLOS One.2025; 20(12): e0338702. CrossRef
Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies Hui Ma, Qing-Zhu Yan, Jing-Ru Ma, Dong-Fu Li, Jun-Ling Yang World Journal of Gastroenterology.2024; 30(10): 1295. CrossRef
Hepatitis B virus genotypes in precision medicine of hepatitis B-related hepatocellular carcinoma: Where we are now Caecilia H C Sukowati, Sri Jayanti, Turyadi Turyadi, David H Muljono, Claudio Tiribelli World Journal of Gastrointestinal Oncology.2024; 16(4): 1097. CrossRef
N-Hydroxypiridinedione: A Privileged Heterocycle for Targeting the HBV RNase H Dimitrios Moianos, Maria Makri, Georgia-Myrto Prifti, Aristeidis Chiotellis, Alexandros Pappas, Molly E. Woodson, Razia Tajwar, John E. Tavis, Grigoris Zoidis Molecules.2024; 29(12): 2942. CrossRef
SOD1 inhibition enhances sorafenib efficacy in HBV‐related hepatocellular carcinoma by modulating PI3K/Akt/mTOR pathway and ROS‐mediated cell death Jooyoung Lee, Jiye Kim, Ryunjin Lee, Eunkyeong Lee, Hye‐In An, Yong‐Jae Kwon, Hana Jin, Chan‐Gi Pack, Inki Kim, Young‐In Yoon, Gil‐Chun Park, Eun‐Kyoung Jwa, Jae Hyun Kwon, Jung‐Man Namgoong, Gi‐Won Song, Shin Hwang, Eunyoung Tak, Sung‐Gyu Lee Journal of Cellular and Molecular Medicine.2024;[Epub] CrossRef
Rupestonic Acid Derivative YZH-106 Promotes Lysosomal Degradation of HBV L- and M-HBsAg via Direct Interaction with PreS2 Domain Lanlan Liu, Haoyu Wang, Lulu Liu, Fang Cheng, Haji Akber Aisa, Changfei Li, Songdong Meng Viruses.2024; 16(7): 1151. CrossRef
Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim Clinical and Molecular Hepatology.2024; 30(3): 539. CrossRef
Diagnostic Utility of Pre-Genomic Hepatitis B RNA in the Evaluation of HBV/HIV Coinfection Kenneth Sherman, Susan Rouster, Heidi Meeds, Marion Peters, Jason Blackard, Paul Horn, Timothy Archampong, Awewura Kwara, Mark Anderson, Michael Stec, Gavin Cloherty Pathogens and Immunity.2024; 9(2): 43. CrossRef
Functional cure of chronic hepatitis B-hope or hype? Gautam Ray World Journal of Hepatology.2024; 16(9): 1199. CrossRef
Differential T-cell profiles determined by Hepatitis B surface antigen decrease among people with Human Immunodeficiency Virus /Hepatitis B Virus coinfection on treatment Xiaodi Li, Ling Xu, Lianfeng Lu, Xiaosheng Liu, Yang Yang, Yuanni Wu, Ting Zhu, Xiaoxia Li, Yanling Li, Xiaojing Song, Yang Han, Wei Lyu, Wei Cao, Taisheng Li Journal of Translational Medicine.2024;[Epub] CrossRef
Class II transactivator restricts viral replication, extending its effect to HBV: Editorial on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction” Cho-Rong Lee, Sung-Gyoo Park Clinical and Molecular Hepatology.2024; 30(4): 724. CrossRef
Correspondence on editorial regarding “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction” Mehrangiz Dezhbord, Kyun-Hwan Kim Clinical and Molecular Hepatology.2024; 30(4): 1028. CrossRef
A case report: cccDNA and pgRNA remain positive in liver tissue in a chronic hepatitis B patient with functional cure Wenxiong Xu, Qiumin Luo, Yeqiong Zhang, Chan Xie, Liang Peng Frontiers in Medicine.2024;[Epub] CrossRef
Antiviral Therapy for Chronic Hepatitis B Infection Improves Outcomes After Total Hip Arthroplasty: A Multicenter Retrospective Study Tao Cheng, Guoyong Li, Huiming Ning, Liang Hao The Journal of Arthroplasty.2023; 38(2): 300. CrossRef
The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(1): 99. CrossRef
Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB” Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen Clinical and Molecular Hepatology.2023; 29(1): 191. CrossRef
Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2023; 29(1): 113. CrossRef
Overview of the development of HBV small molecule inhibitors Huihui Yang, Weiwei Yao, Jinfei Yang European Journal of Medicinal Chemistry.2023; 249: 115128. CrossRef
The progress of molecules and strategies for the treatment of HBV infection Youlu Pan, Heye Xia, Yanwen He, Shenxin Zeng, Zhengrong Shen, Wenhai Huang Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef
Spermidine enhances the efficacy of adjuvant in HBV vaccination in mice Daisuke Ito, Hiroyasu Ito, Tatsuya Ando, Yasuhiro Sakai, Takayasu Ideta, Ken J. Ishii, Tetsuya Ishikawa, Masahito Shimizu Hepatology Communications.2023;[Epub] CrossRef
The role of different viral biomarkers on the management of chronic hepatitis B Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen Clinical and Molecular Hepatology.2023; 29(2): 263. CrossRef
The latest global burden of liver cancer: A past and present threat Joo Hyun Oh, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(2): 355. CrossRef
Interactions of Na+/taurocholate cotransporting polypeptide with host cellular proteins upon hepatitis B and D virus infection: novel potential targets for antiviral therapy Dariusz Zakrzewicz, Joachim Geyer Biological Chemistry.2023; 404(7): 673. CrossRef
Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy Jae Seung Lee, Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Beom Seok Kim, Seung Up Kim Alimentary Pharmacology & Therapeutics.2023; 58(1): 99. CrossRef
Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study Heejin Cho, Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang BMC Gastroenterology.2023;[Epub] CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy Beom Kyung Kim, Sang Hoon Ahn Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Osamu Yoshida, Julio Aguilar, Guillen Nieto Gerardo, Yoichi Hiasa Biomedicines.2023; 11(7): 1944. CrossRef
Chronic Hepatitis B Infection: Current and Emerging Therapeutic
Strategies Ankita Singh, Jitendra Kumar, Vijay Kumar Current Topics in Medicinal Chemistry.2023; 23(18): 1727. CrossRef
Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA An-Qi Zhuang, Yan Chen, Shan-Mei Chen, Wen-Cheng Liu, Yao Li, Wen-Jie Zhang, Yi-Hang Wu Viruses.2023; 15(12): 2315. CrossRef
Multitasking Na+/Taurocholate Cotransporting Polypeptide (NTCP) as a Drug Target for HBV Infection: From Protein Engineering to Drug Discovery Dariusz Zakrzewicz, Joachim Geyer Biomedicines.2022; 10(1): 196. CrossRef
Genotypes Variation and Molecular Epidemiology Of The Hbv Chronic Liver Infection In The Local Population Of Pakistan: An Overview Of The Recent Literature Bushra Tahreem, Ghadir Ali, Haroon Ahmad, Asim Shahzad, Muhammad Khurram, Nabiha Naeem, Aquib Nazar, Muhammad Haris, Hassan ., Shahrukh . Pakistan BioMedical Journal.2022;[Epub] CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef
Current Status of Drug Therapy for Chronic Hepatitis B 显明 尹 Advances in Clinical Medicine.2022; 12(07): 6196. CrossRef
Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B Chan‐Young Jung, Hyung Woo Kim, Jung Il Lee, Hyun Woong Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim Liver International.2022; 42(11): 2408. CrossRef
Design, Synthesis and Evaluation of Novel 4‐(4‐Chlorobenzyl)‐6‐methylpyridazin‐3(2H)‐one Derivatives as Hepatitis B Virus Inhibitors Oya Unsal Tan, Jan Moncol, David Durantel ChemistrySelect.2022;[Epub] CrossRef
Hepatitis B functional cure and immune response Jia-Rui Zheng, Zi-Long Wang, Bo Feng Frontiers in Immunology.2022;[Epub] CrossRef
Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim Diagnostics.2022; 13(1): 3. CrossRef
Critical Updates on Chronic Hepatitis B Virus Infection in 2021 Cyriac A Philips, Rizwan Ahamed, Jinsha K Abduljaleel, Sasidharan Rajesh, Philip Augustine Cureus.2021;[Epub] CrossRef
Association of HBV serological markers with host antiviral immune response relevant hepatic inflammatory damage in chronic HBV infection Bei Jiang, Leijie Wang, Huan Liu, Lin Wang, Rui Su, Liang Xu, Guochao Wei, Jia Li, Fengmin Lu, Xiangmei Chen Journal of Medical Virology.2024;[Epub] CrossRef
Although patients with cirrhosis are known to be in a state of “rebalance” in that pro- and anticoagulant factors increase the risk for both bleeding and thrombosis, the prevalence of portal vein thrombosis (PVT) in patients with cirrhosis can be up to 26%. Therefore, physicians should consider anticoagulation for the prevention and management of PVT in patients with cirrhosis who are at high risk of PVT. Vitamin K antagonist or low molecular weight heparin is suggested as the standard treatment for PVT in cirrhosis. With the advent of new direct-acting oral anticoagulants (DOACs), there is a paradigm shift of switching to DOACs for the treatment of PVT in patients with cirrhosis. However, the safety and efficacy of DOACs in the treatment of PVT was not well-known in patients with cirrhosis. Therefore, this review focused on the current knowledge about the efficacy, safety concerns, and hepatic metabolism of DOACs in patients with cirrhosis and PVT.
Citations
Citations to this article as recorded by
A glycoprotein UGP2A from the medicinal insect Ulomoides dermestoides alleviates deep vein thrombosis via the TLR4/MyD88 signaling pathway Qun Yu, Caiyi Wang, Yadan Dong, Mingrong Li, Ting Yan, Heng Liu, Chenggui Zhang, Jiapeng Wang, Huai Xiao International Journal of Biological Macromolecules.2026; 341: 150216. CrossRef
Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival Madhumita Premkumar, Harish Bhujade, Prerna Sharma, Jasvinder Nain, Jasmina Ahluwalia, Anchal Sandhu, Yogendra Kumar, Sahaj Rathi, Sunil Taneja, Ajay Kumar Duseja, Anand V. Kulkarni, Charanpreet Singh, Shano Naseem, Tanka Karki, Pankaj Gupta, Sreedhara B. Alimentary Pharmacology & Therapeutics.2025; 61(6): 971. CrossRef
Comprehensive approach to liver cirrhosis treatment: Integrating ayurveda, homeopathy, and allopathy Debabrata Dash, Palak Kesharwani, Raj Kumar Koiri Pharmacological Research - Natural Products.2025; 6: 100184. CrossRef
The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis Seema Sharma, Nishant Tiwari, Sampat Singh Tanwar Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(9): 11541. CrossRef
Machine learning models predict coagulopathy in traumatic brain injury patients in ER Haoyu Wang, Wenying Cao, Jianhuang Huang, Yuxing Feng, Cheng Li Frontiers in Neurology.2025;[Epub] CrossRef
Effect of Direct Oral Anticoagulants Versus Traditional Anticoagulation in Budd-Chiari Syndrome Xiaojuan Wu, Lijuan Liang, Jinghong Liu Clinical and Applied Thrombosis/Hemostasis.2025;[Epub] CrossRef
The relationship between gastroduodenal lesions and coronary heart disease N. U. Chamsutdinov, Ja. N. Abdulmanapova, N. A. Alieva, K. L. Seydalieva, A. R. Arbukhanova, M. A. Alakhverdieva, Z. M. Magomedova, R. G. Biybolatova Meditsinskiy sovet = Medical Council.2025; (15): 58. CrossRef
Comparative Effectiveness and Safety of Various Anticoagulation Regimens for Portal Venous Thrombosis in Cirrhosis: A Systematic Review and Network Meta-Analysis Zain ul Abideen, Muhammad Hassan Waseem, Noor Ul Huda Ramzan, Hamna Raheel, Fariha Hasan, Pawan Kumar Thada, Prasun K. Jalal Clinical and Applied Thrombosis/Hemostasis.2025;[Epub] CrossRef
Analysis of Related Influencing Factors of Portal Vein Thrombosis After Hepatectomy ShiGuai Qi, Jie Tao, Xinhua Wu, Xu Feng, Guoying Feng, Zhengrong Shi Journal of Laparoendoscopic & Advanced Surgical Techniques.2024; 34(3): 246. CrossRef
Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin in Cirrhotic Patients: A Systematic Review and Meta-Analysis Chunwei Cheng, Juan Hua, Liang Xiong Clinical and Applied Thrombosis/Hemostasis.2024;[Epub] CrossRef
Direct Oral Anticoagulants Versus Traditional Anticoagulation in Cirrhotic Patients with Portal Vein Thrombosis: Updated Systematic Review Xiulin Xiao, Wengen Zhu, Qixin Dai Clinical and Applied Thrombosis/Hemostasis.2024;[Epub] CrossRef
Portal Vein Variations, Clinical Correlation, and Embryological Explanation: A Review Article Gareema Tyagi, Roshan K Jha Cureus.2023;[Epub] CrossRef
THE SURGEON'S PERSPECTIVE ON PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS S.M. Vasyliuk, V.I. Hudyvok, І.R. Labiak, N.M. Pavliuk, V.M. Atamaniuk Art of Medicine.2023; : 152. CrossRef
Heparins for prevention and treatment of venous thromboembolism in cirrhosis: Research advances Zhe Li, Wen-Tao Xu, Xiang-Bo Xu, Xing-Shun Qi World Chinese Journal of Digestology.2022; 30(9): 381. CrossRef
Letter to the editor: Treating portal vein thrombosis in cirrhosis: is anticoagulation therapy overestimated? Xiaobing Wang, Liping Chen Hepatology International.2022; 16(5): 1248. CrossRef
Direct oral anticoagulants (DOACs): From the laboratory point of view Sandra Margetić, Sandra Šupraha Goreta, Ivana Ćelap, Marija Razum Acta Pharmaceutica.2022; 72(4): 459. CrossRef
Goh Eun Chung, Eun Ju Cho, Jeong-Hoon Lee, Jeong-ju Yoo, Minjong Lee, Yuri Cho, Dong Hyeon Lee, Hwi Young Kim, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Fabien Zoulim
Clin Mol Hepatol 2017;23(1):66-73. Published online February 14, 2017
Background/Aims A recent study reported that entecavir had inferior efficacy in nucleos(t)ide analogue (NA)-experienced chronic hepatitis B (CHB) patients compared to NA-naïve patients. We sought to compare the efficacy of tenofovir disoproxil fumarate (TDF) in NA-experienced and NA-naïve CHB patients.
Methods We retrospectively enrolled 252 consecutive patients who had a serum hepatitis B virus (HBV) DNA level greater than 2,000 IU/mL at the initiation of TDF treatment and who received TDF for at least 6 months. Complete virologic suppression (CVS) was defined as undetectable serum HBV DNA. We generated a multivariate Cox proportional-hazard model to examine predictive factors that were independently associated with time to CVS.
Results The mean age of patients was 48.2 years, and the cohort included 181 NA-naïve patients and 71 NA-experienced patients. The median duration of TDF treatment was 14.4 (interquartile range, 9.5-17.8) months. A total of 167 (92.3%) of 181 NA-naïve patients achieved CVS, and 60 (84.5%) of 71 NA-exposed patients achieved CVS. Forty-nine (89.1%) of 55 patients who previously took an NA aside from adefovir and 11 (68.8%) of 16 adefovir-experienced patients achieved CVS. In multivariable analysis, previous adefovir exposure significantly influenced time to CVS (hazard ratio, 0.37; 95% confidence interval, 0.19-0.72; P=0.003), after adjusting for HBeAg positivity, baseline HBV DNA level and cirrhosis.
Conclusions Tenofovir had inferior efficacy in adefovir-experienced CHB patients compared to NA-naïve patients. The response of patients with previous adefovir exposure to TDF monotherapy should be monitored closely.
Citations
Citations to this article as recorded by
Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough? Xieer Liang, Qing Xie, Jia Shang, Hong Tang, Min Xu, Qinghua Meng, Jiming Zhang, Pujun Gao, Jifang Sheng, Hao Wang, Jidong Jia, Guiqiang Wang, Shunquan Wu, Jingna Ping, Jinlin Hou Journal of Gastroenterology and Hepatology.2022; 37(3): 471. CrossRef
Switching from Tenofovir-Based Combination Therapy to Tenofovir Monotherapy in Multidrug-Experienced Chronic Hepatitis B Patients: a 5-Year Experience at Two Centers Jung Hun Kim, Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Byung-chul Yoo, Eileen L. Yoon, Seong Hee Kang Antimicrobial Agents and Chemotherapy.2022;[Epub] CrossRef
Clinical effects of NTCP‐inhibitor myrcludex B Dongliang Cheng, Bing Han, Wei Zhang, Wei Wu Journal of Viral Hepatitis.2021; 28(6): 852. CrossRef
Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs Daiki Yamashige, Tetsuya Hosaka, Fumitaka Suzuki, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada Journal of Gastroenterology.2021; 56(11): 1008. CrossRef
Tenofovir‐based combination therapy or monotherapy for multidrug‐resistant chronic hepatitis B: Long‐term data from a multicenter cohort study Hyung Joon Yim, Sang Jun Suh, Young Kul Jung, Seong Gyu Hwang, Yeon Seok Seo, Soon Ho Um, Sae Hwan Lee, Young Seok Kim, Jae Young Jang, In Hee Kim, Hyoung Su Kim, Ji Hoon Kim, Young Sun Lee, Eileen L. Yoon, Myeong Jun Song, Jun Yong Park Journal of Viral Hepatitis.2020; 27(12): 1306. CrossRef
Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients Eun-Sook Park, Ah Ram Lee, Doo Hyun Kim, Jeong-Hoon Lee, Jeong-Ju Yoo, Sung Hyun Ahn, Heewoo Sim, Soree Park, Hong Seok Kang, Juhee Won, Yea Na Ha, Gu-Choul Shin, So Young Kwon, Yong Kwang Park, Byeong-Sun Choi, Yun Bin Lee, Nakcheol Jeong, Yohan An, Youn Journal of Hepatology.2019; 70(6): 1093. CrossRef
Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate In Suk Min, Chang Hun Lee, Ik Sang Shin, Na Eun Lee, Hong Seon Son, Seung Bum Kim, Seung Young Seo, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, In Hee Kim Gut and Liver.2019; 13(1): 93. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2019; 25(2): 93. CrossRef
Direct Detection of Drug-Resistant Hepatitis B Virus in Serum Using a Dendron-Modified Microarray Doo Hyun Kim, Hong Seok Kang, Seong-Suk Hur, Seobo Sim, Sung Hyun Ahn, Yong Kwang Park, Eun-Sook Park, Ah Ram Lee, Soree Park, So Young Kwon, Jeong-Hoon Lee, Kyun-Hwan Kim Gut and Liver.2018; 12(3): 331. CrossRef
Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients? Sung Won Chung, Young Chang, Hyo Young Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim Gastroenterology Research and Practice.2018; 2018: 1. CrossRef
Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus? Yun Bin Lee, Jeong-Hoon Lee Clinical and Molecular Hepatology.2017; 23(3): 219. CrossRef
First
Prev
